Neumora Therapeutics (NMRA) Interest Expenses (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Interest Expenses of $1.9 million for Q1 2026, down 8.94% quarter-over-quarter from $2.0 million in Q4 2025.
Neumora Therapeutics (NMRA) Interest Expenses (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Interest Expenses history runs 5 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Interest Expenses changed N/A year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $3.9 million (changed N/A YoY), while the FY2025 annual figure was $330.2 million, up 24.89% from the prior year.
- Interest Expenses for Q1 2026 stood at $1.9 million, down from $2.0 million in the prior quarter.
- The five-year high for Interest Expenses was $197.3 million in Q4 2023, with the low at $1.0 million in Q3 2025.
- The 5-year median for Interest Expenses is $58.3 million (2024), against an average of $66.6 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 39.36% in 2023, then plunged 98.63% in 2025.
- Neumora Therapeutics' Interest Expenses stood at $141.6 million in 2022, then jumped by 39.36% to $197.3 million in 2023, then slumped by 63.02% to $73.0 million in 2024, then tumbled by 97.21% to $2.0 million in 2025, then fell by 8.94% to $1.9 million in 2026.
- Business Quant data shows NMRA's Interest Expenses at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 1.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.85 Mn |
| Mar 31, 2026 | 1.85 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Sep 30, 2024 | 72.96 Mn |
| Sep 30, 2024 | 72.96 Mn |
| Jun 30, 2024 | 43.68 Mn |
| Jun 30, 2024 | 43.68 Mn |
| Mar 31, 2024 | 90.74 Mn |
| Mar 31, 2024 | 90.74 Mn |
| Dec 31, 2023 | 197.28 Mn |
| Dec 31, 2023 | 197.28 Mn |
| Sep 30, 2023 | 113.85 Mn |
| Sep 30, 2023 | 113.85 Mn |
| Dec 31, 2022 | 141.56 Mn |
| Dec 31, 2022 | 141.56 Mn |